focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 487.50
Bid: 482.50
Ask: 489.50
Change: 0.00 (0.00%)
Spread: 7.00 (1.451%)
Open: 487.50
High: 487.50
Low: 487.50
Prev. Close: 487.50
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update & Notice of Results

10 Apr 2024 07:00

RNS Number : 9365J
Treatt PLC
10 April 2024
 

 

10 April 2024

 

TREATT PLC

("Treatt" or "the Group")

 

Half Year Trading Update and Notice of Results

Solid performance in H1 2024, with sales accelerating in the second quarter and year-on-year profit growth

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, announces the following trading update for the half year ended 31 March 2024 (the "Period").

HIGHLIGHTS:

· Profit before tax and exceptional items (PBTE) expected to be marginally ahead of prior year at c.£7.5m (H1 2023: £7.3m).

· H1 revenue of £72.1m (H1 2023: £76.0m), reflecting a subdued Q1 from the impact of destocking as expected and previously indicated; and an acceleration in Q2, with sales growing by 5.1% (7.7% in constant currency) compared to the same quarter in FY 2023.

· New wins in Premium products and in China, with both areas growing during H1.

· Improved net operating margin of c.11.0% (H1 2023: 10.1%), reflecting embedded cost disciplines and self-help measures

· Net debt unchanged from 30 September 2023 at £10.3m (FY 2023: £10.4m), reflecting higher citrus commodity prices and high receivables at period end from strong March sales; however good cash generation expected in H2 as receivables convert to cash

· Looking to H2, we have a solid sales order book and healthy sales pipeline

· H2 full year PBTE anticipated to be in line with the Board's expectations.

H1 2024 Performance

Revenue for the half year declined by 5.1% (2.7% decline in constant currency) to £72.1m (FY 2023: £76.0m) as anticipated. Q1, which is typically our quietest quarter, saw a decline year on year due to destocking, however sales were 5.1% ahead (7.7% in constant currency) in Q2 as destocking softened, as expected.

Heritage sales declined by 6.0% (constant currency) as citrus customers elected for cheaper alternatives because of sustained high orange oil prices. Despite this, we continue to support our customers with innovative and differentiating solutions. Within Heritage, Synthetic Aroma was up 3.9% (constant currency), which we consider to be reflective of demand returning in this category which was impacted by destocking in FY23.

Our higher margin Premium categories grew 11.6% (constant currency), with multiple wins in Tea in the North American market. Premium is typically H2 weighted, and as such we expect further sales and margin growth in the second half.

In New Markets, China grew 3.3% (constant currency), securing further wins in leading local beverage brands and we have established a broader base of local manufacturing partners. In line with our strategic ambition we have commenced the scale up of our global Treattzest manufacturing capacity, and this product will be relaunched in April.

Balance sheet

The Group ended the half year with net debt of £10.3m (FY 2023: £10.4m). We continue to focus on working capital management and have successfully reduced inventory volume by 5.6% since September 2023 (16.7% lower than the comparable period), offset by higher commodity prices and seasonal build for strategic and premium demand. An increase in receivables reflects the strong finish to the half year trading and we anticipate a reduction in net debt in the second half, in line with Board expectations.

Ryan Govender, Interim CEO, commented:

"Treatt delivered a robust performance in the first half, making good progress in line with our strategic goals. We are particularly pleased with progress in China, where we continued to invest and consolidate our position, and in our higher margin Premium categories where we have a number of active pipeline opportunities. Momentum in the second quarter was strong, and we recorded our highest ever monthly revenue in March.

As we enter the second half, we are encouraged by our solid order book and healthy sales pipeline. The Board continues to expect to report full year PBTE in line with expectations."

Notice of results

Treatt's results for the half year ended 31 March 2024 are expected to be announced on 14 May 2024.

Treatt plc +44 (0)1284 702500

Ryan Govender Interim Chief Executive Officer

Alison Sleight Interim Chief Financial Officer

 

Joint Brokers

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

 

Peel Hunt LLP +44 (0) 20 7418 8900

George Sellar

Mike Burke

 

Financial PR

MHP +44(0) 20 3128 8100

Tim Rowntree Treatt@mhpgroup.com

Eleni Menikou 

Catherine Chapman

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSDSAIAIIS
Date   Source Headline
12th May 20207:00 amRNSHalf year/Interim Report
11th May 20208:53 amRNSHolding(s) in Company
7th May 20203:48 pmRNSHolding(s) in Company
6th May 20204:23 pmRNSHolding(s) in Company
29th Apr 202012:51 pmRNSDisclosure of rights attached to equity shares
27th Apr 202012:08 pmRNSSecond Price Monitoring Extn
27th Apr 202012:03 pmRNSPrice Monitoring Extension
24th Apr 20202:12 pmRNSHolding(s) in Company
23rd Apr 20206:23 pmRNSDirector/PDMR Shareholding
17th Apr 20202:06 pmRNSSID and Board Committee Changes
14th Apr 20204:36 pmRNSHolding(s) in Company
9th Apr 20204:43 pmRNSHolding(s) in Company
9th Apr 20204:19 pmRNSTR:1 notification of major holdings
7th Apr 20207:00 amRNSTrading update
26th Mar 202012:07 pmRNSSecond Price Monitoring Extn
26th Mar 202012:02 pmRNSPrice Monitoring Extension
23rd Mar 20205:15 pmRNSDirector/PDMR Shareholding
23rd Mar 202012:07 pmRNSSecond Price Monitoring Extn
23rd Mar 202012:03 pmRNSPrice Monitoring Extension
18th Mar 202010:38 amRNSHolding(s) in Company
12th Mar 20204:40 pmRNSPrice Monitoring Extension
18th Feb 20205:15 pmRNSHolding(s) in Company
10th Feb 20205:29 pmRNSHolding(s) in Company
6th Feb 20209:04 amRNSHolding(s) in Company
5th Feb 20203:53 pmRNSVoting Rights and Capital
31st Jan 20204:54 pmRNSResult of AGM
29th Jan 20205:26 pmRNSDirector/PDMR Shareholding
29th Jan 20205:10 pmRNSHolding(s) in Company
21st Jan 20203:21 pmRNSHolding(s) in Company
21st Jan 20201:26 pmRNSHolding(s) in Company
17th Jan 20203:28 pmRNSDirector/PDMR Shareholding
16th Jan 20205:07 pmRNSHolding(s) in Company
9th Jan 20202:28 pmRNSDirector/PDMR Shareholding - Replacement
8th Jan 20205:04 pmRNSDirector/PDMR Shareholding
7th Jan 20205:16 pmRNSHolding(s) in Company
6th Jan 202011:18 amRNSDirector/PDMR Shareholding
24th Dec 201910:54 amRNSVoting Rights and Capital
18th Dec 20194:03 pmRNSNotification of Transactions of Directors
17th Dec 20194:04 pmRNSDirector/PDMR Shareholding
10th Dec 201912:15 pmRNSAnnual Report
6th Dec 20194:12 pmRNSHolding(s) in Company
2nd Dec 20194:44 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Dec 20194:43 pmRNSBLOCK LISTING SIX MONTHLY RETURN
26th Nov 20197:00 amRNSFinal Results
25th Nov 201912:07 pmRNSSecond Price Monitoring Extn
25th Nov 201912:02 pmRNSPrice Monitoring Extension
22nd Nov 20194:35 pmRNSPrice Monitoring Extension
21st Nov 20193:11 pmRNSBoard Committee Change
6th Nov 20199:44 amRNSHolding(s) in Company
25th Oct 20194:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.